{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:46:13Z","timestamp":1792071973506,"version":"4.4.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed\/refractory (r\/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international SCHOLAR-5 cohort, which applied key ZUMA-5 trial eligibility criteria simulating randomized controlled trial conditions. SCHOLAR-5 data were extracted from institutions in 5 countries, and from 1 historical clinical trial, for r\/r FL patients who initiated a third or higher line of therapy after July 2014. Patient characteristics were balanced through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. Time-to-event outcomes were evaluated using weighted Kaplan-Meier analysis. Overall response rate (ORR) and complete response (CR) rate were compared using weighted odds ratios. The 143 ScHOLAR-5 patients reduced to an effective sample of 85 patients after SMR weighting vs 86 patients in ZUMA-5. Median follow-up time was 25.4 and 23.3 months for SCHOLAR-5 and ZUMA-5. Median overall survival (OS) and progression-free survival (PFS) in SCHOLAR-5 were 59.8 months and 12.7 months and not reached in ZUMA-5. Hazard ratios for OS and PFS were 0.42 (95% confidence interval [CI], 0.21-0.83) and 0.30 (95% CI, 0.18-0.49). The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 and 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95% CI, 5.6-46.9) and 8.9 (95% CI, 4.3-18.3). Compared with available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints, suggesting axi-cel addresses an important unmet need for r\/r FL patients. This trial was registered at www.clinicaltrials.gov as #NCT03105336.<\/jats:p>","DOI":"10.1182\/blood.2021014375","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T18:52:41Z","timestamp":1654800761000},"page":"851-860","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-7954","authenticated-orcid":false,"given":"Paola","family":"Ghione","sequence":"first","affiliation":[{"name":"1Roswell Park Comprehensive Cancer Center, Buffalo, NY;"},{"name":"2Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"2Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-8904","authenticated-orcid":false,"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[{"name":"3Kite, A Gilead Company, Santa Monica, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7381-680X","authenticated-orcid":false,"given":"Sabela","family":"Bobillo","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Vall D'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-2137","authenticated-orcid":false,"given":"Kevin","family":"Deighton","sequence":"additional","affiliation":[{"name":"5Delta Hat, Nottingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"6Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Nahas","sequence":"additional","affiliation":[{"name":"3Kite, A Gilead Company, Santa Monica, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-326X","authenticated-orcid":false,"given":"Anthony J.","family":"Hatswell","sequence":"additional","affiliation":[{"name":"5Delta Hat, Nottingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Scott","family":"Jung","sequence":"additional","affiliation":[{"name":"3Kite, A Gilead Company, Santa Monica, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5398","authenticated-orcid":false,"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"7RainCity Analytics, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0017-4863","authenticated-orcid":false,"given":"Julia Thornton","family":"Snider","sequence":"additional","affiliation":[{"name":"3Kite, A Gilead Company, Santa Monica, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"8Division of Cancer Medicine, Department of Lymphoma and Myeloma,The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-8184","authenticated-orcid":false,"given":"Maria Teresa","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"9Portuguese Oncology Institute of Porto, Porto, Portugal;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alan","family":"Brookhart","sequence":"additional","affiliation":[{"name":"10Target Real World Evidence (RWE), Durham, NC;"},{"name":"11Department of Population Health Sciences, Duke University, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[{"name":"12Hopital Lyon Sud, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"13The Christie National Health Service (NHS) Foundation Trust and University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-7430","authenticated-orcid":false,"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"14Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2022082515224287200_B1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol."},{"issue":"6","key":"2022082515224287200_B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2022082515224287200_B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica."},{"issue":"16","key":"2022082515224287200_B4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"issue":"5","key":"2022082515224287200_B5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"issue":"7","key":"2022082515224287200_B6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"issue":"4","key":"2022082515224287200_B7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.15149","article-title":"Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study","volume":"184","author":"Link","year":"2019","journal-title":"Br J Haematol."},{"issue":"23","key":"2022082515224287200_B8","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022082515224287200_B9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical endpoint of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood."},{"issue":"8","key":"2022082515224287200_B10","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022082515224287200_B11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022082515224287200_B12","doi-asserted-by":"crossref","first-page":"e19548","DOI":"10.1200\/JCO.2021.39.15_suppl.e19548","article-title":"Clinical outcomes in patients relapsed\/refractory after \u2265 2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis","volume":"39","author":"Kanters","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022082515224287200_B13","first-page":"40","article-title":"Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood."},{"key":"2022082515224287200_B14","doi-asserted-by":"crossref","first-page":"hon.26_2880","DOI":"10.1002\/hon.26_2880","article-title":"Outcomes in later-lines of therapy for relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"39","author":"Ghione","year":"2021","journal-title":"Hematol Oncol."},{"issue":"11","key":"2022082515224287200_B15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2022082515224287200_B16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022082515224287200_B17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol."},{"key":"2022082515224287200_B18","volume-title":"Causal Inference: What If.","author":"Hern\u00e1n","year":"2020"},{"issue":"12","key":"2022082515224287200_B19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol."},{"issue":"1","key":"2022082515224287200_B20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol."},{"issue":"973","key":"2022082515224287200_B21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3389\/fphar.2019.00973","article-title":"Propensity Score methods in health technology assessment: principles, extended applications, and recent advances","volume":"10","author":"Ali","year":"2019","journal-title":"Front Pharmacol."},{"key":"2022082515224287200_B22","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2021-145407","article-title":"Healthcare resource utilization and costs of patients with relapsed\/refractory follicular lymphoma receiving 3 or more lines of therapy","volume":"138","author":"Matasar","year":"2021","journal-title":"Blood."},{"key":"2022082515224287200_B23","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood-2021-149327","article-title":"Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma","volume":"138","author":"Salles","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2022082515224287200_B24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-20-1301","article-title":"The future of clinical trial design in oncology","volume":"11","author":"Spreafico","year":"2021","journal-title":"Cancer Discov."},{"issue":"6","key":"2022082515224287200_B25","doi-asserted-by":"crossref","first-page":"e011666","DOI":"10.1136\/bmjopen-2016-011666","article-title":"Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014","volume":"6","author":"Hatswell","year":"2016","journal-title":"BMJ Open."},{"key":"2022082515224287200_B26","article-title":"Summary Basis for Regulatory Action","author":"FDA"},{"issue":"7","key":"2022082515224287200_B27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"22","key":"2022082515224287200_B28","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2022082515224287200_B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B-cell lymphoma in the United States","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"27","key":"2022082515224287200_B30","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/8\/851\/1916683\/bloodbld2021014375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/8\/851\/1916683\/bloodbld2021014375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T15:25:38Z","timestamp":1661441138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/8\/851\/485518\/Comparative-effectiveness-of-ZUMA-5-axi-cel-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014375","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}